Phoenestra

What Phoenestra does

Phoenestra GmbH is an Austrian pre-clinical biotechnology company founded in 2018 and headquartered in Linz that develops stem-cell-derived products and extracellular vesicle (EV) therapeutics for regenerative medicine. Its portfolio centers on three technology platforms — MSCale™ (scalable mesenchymal stem cell expansion in stirred tank bioreactors using microcarriers), EVscale™ (extracellular vesicle production via a patented continuous perfusion process), and MSC/TERT (telomerized MSCs licensed from Evercyte with extended lifespan beyond 50 population doublings) — plus a virus-free iPSC reprogramming capability.

The company's therapeutic pipeline targets diabetic wound treatment (pre-clinical, with data published November 2025), cardioprotection/reperfusion injury (discovery), and undisclosed indications. Underlying bioprocessing is GMP-aligned by design, with tiered cell banking and CMC strategies established early, although a certified GMP cleanroom is still being built out. The company also offers an MSC-EV catalogue of R&D-grade preparations and R&D services including cell line and process development, EV characterization (particle sizing, tetraspanin/MSC marker phenotyping, bioassays for anti-inflammation, anti-fibrosis, and wound healing, plus miRNA profiling via TAmiRNA), and cell characterization (STR profiling, karyotyping, differentiation).

Commercially, Phoenestra operates a direct B2B model selling research- and GMP-grade products and bespoke services to pharmaceutical companies, biotech firms, academic institutions, and CROs on a quote-based, contact-driven basis ([email protected], [email protected]). Revenue is not disclosed; the operational team is 7 people plus a 5-member advisory board. Strategic partnerships are deep within the Austrian regenerative-medicine ecosystem — Evercyte (telomerized MSC license and bioassays), TAmiRNA (miRNA services), LBI Trauma (research collaboration), FFG (funding), and multiple Austrian and international universities — but no venture funding rounds have been publicly disclosed.

Name

Phoenestra

Legal name

Phoenestra GmbH

Website

https://phoenestra.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Phoenestra GmbH is an Austrian pre-clinical biotechnology company developing GMP-aligned stem cell (MSC, iPSC) and extracellular vesicle therapeutics, primarily for diabetic wound healing and cardioprotection, sold directly to pharmaceutical, biotech, and academic customers.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAGAA

Stem Cell–Based Regenerative Therapies

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAABAE

Stem Cell Therapies (MSC/iPSC/HSC-derived)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAAKAC

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

SECONDARYHLAAABAL

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

• Stem cell products
• Extracellular vesicles
• Regenerative medicine
• Bioprocess development
• GMP cell manufacturing

Headquarters

HQ city

Linz

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Stem Cell and EV Product Sales: Sale of research-grade and GMP-grade stem cell products (MSCs, iPSCs) and extracellular vesicle preparations. R&D-grade EV preparations available for testing with controlled processing and extensive analytical data.
2. R&D and GMP Services: Comprehensive service offerings including cell line and process development, extracellular vesicle characterization, and cell characterization services for pharmaceutical, biotech, and academic customers.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Phoenestra develops and manufactures GMP-ready stem cell products and extracellular vesicle (EV) preparations derived from Mesenchymal Stem Cells (MSCs) and induced Pluripotent Stem Cells (iPSCs). Its portfolio includes the MSCale™ scalable MSC expansion platform, telomerized MSC/TERT cell lines, EVscale™ EV products, and iPSC lines, complemented by R&D and GMP services for cell line development, bioprocess scale-up, and EV/cell characterization for pharmaceutical, biotech, and academic customers.

Product overview

Phoenestra offers a portfolio of stem cell products and EV-based therapeutics organized around three core product lines: MSCale™ (scalable MSC expansion platform), MSC/TERT (telomerized mesenchymal stem cells), EVscale™ (extracellular vesicle products from stem cells), and iPSC (induced pluripotent stem cells). The company also provides associated R&D and GMP services including cell line/process development, EV characterization, and cell characterization. All products are designed for GMP-ready clinical translation with emphasis on reproducibility, scalability, safety, and quality.

Differentiator

Problem solved

Functional benefit

Brands

• MSCale™: Scalable MSC expansion technology platform using stirred tank bioreactors with microcarriers
• EVscale™

Products and services

• MSCale™ Scalable MSC expansion technology platform enabling reproducible expansion of Mesenchymal Stem Cells in stirred tank bioreactors using microcarriers, with tiered Master/Working Cell Banks designed for GMP transfer. For pharmaceutical, biotech, and academic customers developing cell-based therapeutics.
• MSC/TERT (Telomerized MSCs) Telomerized Mesenchymal Stem (Stromal) Cells with extended lifespan exceeding 50 population doublings while preserving MSC morphology and potential, eliminating donor variability, and supplied fully documented for GMP use. For therapeutic developers needing reproducible MSC inputs.
• EVscale™ Extracellular vesicle (exosome) product line derived from stem cells using a patented continuous perfusion process in stirred tank bioreactors, available as native EVs with high biological activity. Designed for fast transfer into GMP facilities; produced without serum, hPL, animal-derived components, antibiotics, or Phenol Red.
• iPSC (Induced Pluripotent Stem Cells) Virus-free reprogrammed induced pluripotent stem cells isolated from human urine, blood, or other sources, with scalable bioreactor-based production, cell banking, and QC. GMP-ready processes using GMP-grade materials; serum-, hPL-, and animal-free and antibiotic-free.
• MSC-EV Catalogue R&D-grade MSC-EV preparations with controlled and standardized processing including final sterile filtration, supplied with extensive analytical and bioactivity data covering anti-Inflammatory, anti-Fibrotic, and Wound Healing activity and consistent marker/microRNA profiles. For pharma, biotech, and academic research use.
• Cell Line and Process Development Services R&D and GMP services covering human iPSC and MSC cell line development, cell banking, stirred-tank bioreactor development and manufacturing (0.25 L scale, DASbox), purification (filtration, TFF, chromatography), upstream and downstream process development, and pre-clinical/early clinical supplies of iPSC, MSC, and MSC-EV preparations.
• Extracellular Vesicle Characterization Services Analytical service covering EV particle concentration and size, tetraspanin and MSC marker phenotyping (CD9, CD63, CD81, CD73, CD90, CD105, CD142, HLA-G, beta2-microglobulin, PD-L1), CD73 activity, lipid content (MemGlow™), miRNA profiling via TAmiRNA, biological activity assays (anti-Inflammation, anti-Fibrosis, wound healing), and sterility/virus/endotoxin testing.
• Cell Characterization Services Service covering cell growth and morphology, surface marker analysis, differentiation, STR profiling, karyotyping, RNA expression analysis via TAmiRNA, particulate and biochemical analytics, bioassays, disease models, and sterility / microbiological purity (incl. mycoplasma), virus, and endotoxin testing.

Quantifiable outcome

• Extended MSC lifespan >50 population doublings while preserving morphology and potential
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Evercyte GmbHcoreTechnology or IntegrationDeep operational relationship through co-founders (Otto Kanzler CFO, Regina Grillari CTO). Evercyte provides commercial license for MSC/TERT telomerized stem cell technology. Phoenestra uses Evercyte's anti-Inflammation and anti-Fibrosis biological activity assays for EV characterization services.
• TAmiRNAcoreTechnology or IntegrationCo-founded by same founders (Otto Kanzler, Regina Grillari, Johannes Grillari). TAmiRNA provides miRNA profiling services and RNA expression analysis used in Phoenestra's cell and EV characterization services.
• Ludwig Boltzmann Institute for Experimental and Clinical Traumatology (LBI Trauma)coreStrategic or Co-development PartnerJohannes Grillari serves as Director of LBI Trauma in Vienna/Austria. Christian Gabriel (advisory board) is part of LBI Trauma. Partnership for research collaboration in regenerative medicine and trauma treatment.
• CytonusminorOthersListed in Partners/Network section - relationship nature not specified in available content
• Fachhochschule Oberösterreich (FH OÖ)minorStrategic or Co-development PartnerListed in Partners/Network section - Austrian university of applied sciences for potential research collaboration
• Johannes Kepler University Linz (JKU)minorStrategic or Co-development PartnerListed in Partners/Network section - local university for potential research and talent collaboration
• Instituto Superior TécnicominorStrategic or Co-development PartnerListed in Partners/Network section - Portuguese technical university for international research collaboration
• MedUni Wien (Medical University of Vienna)minorStrategic or Co-development PartnerListed in Partners/Network section - Austrian medical university for clinical research collaboration
• Tissue RegenerationminorStrategic or Co-development PartnerListed in Partners/Network section - tissue regeneration research network partner
• Medizintechnik-ClusterminorOthersListed in Partners/Network section - Austrian medical technology cluster for industry networking

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• RoosterBio: RoosterBio is a direct peer — it supplies MSCs, MSC-derived EVs, and bioprocess media/tools to cell therapy and regenerative medicine developers. Comparable to Phoenestra on product (MSC/EV), customer base (pharma/biotech/academic), and commercialization model (catalogue product sales plus services).
• Capricor Therapeutics: Capricor is a direct peer developing cell-derived extracellular vesicle therapeutics (CAP-1002, derived from cardiosphere-derived cells) for cardiac and rare disease indications. Closely comparable to Phoenestra's EVscale™ strategy of leveraging stem cell-derived vesicles for cardioprotection and other indications.
• Evox Therapeutics: Evox is a direct peer engineering exosomes/EVs for therapeutic delivery of nucleic acids, proteins, and small molecules. Comparable on the core exosome platform and target customer base (pharma partners for rare disease and CNS indications), with substantially more capital and clinical-stage assets.
• Codiak BioSciences: Codiak pioneered engineered exosome therapeutics (engEx platform) for oncology and rare diseases. Direct peer on the EV therapeutics axis, though Codiak wound down its pipeline in 2023 — illustrating both the promise and capital-intensity risk of the EV therapeutic category Phoenestra is pursuing.

Broad incumbents

• Mesoblast: Mesoblast is a clinical-stage MSC therapy developer (remestemcel-L, rexlemestrocel-L) targeting inflammatory and cardiovascular indications. Comparable on MSC-based therapeutic approach and indication overlap (cardioprotection, inflammatory disease), but a much larger public incumbent with FDA pathway experience.
• Pluristem Therapeutics: Pluristem develops placenta-derived cell therapy products (PLX cells) for wound healing, muscle injury, and hematopoietic indications. Comparable on cell-based regenerative medicine approach and wound healing indication overlap, with broader clinical-stage assets.
• Lonza Cell & Gene Technologies: Lonza is a leading cell therapy CDMO offering MSC, iPSC, and EV manufacturing services at clinical and commercial scale. Comparable on the GMP-aligned cell therapy manufacturing services offered by Phoenestra, but at a vastly larger scale across global facilities.

Emerging players

• Evercyte GmbH: Evercyte is both a licensor (MSC/TERT to Phoenestra) and adjacent peer developing telomerized MSC and iPSC lines for industrial and clinical applications. Comparable on the underlying cell technology platform, with overlapping expertise among co-founders.
• Cellares: Cellares is an emerging player in automated cell therapy manufacturing (Cell Shuttle platform). Comparable to the GMP-aligned, scalable cell therapy manufacturing capability Phoenestra is building, though focused on broader cell therapy automation rather than MSC/EV-specific workflows.

Regional players

• ExoCoBio: ExoCoBio is a Korean-based exosome therapeutics and cosmetic/regenerative medicine company using stem cell-derived EVs. Comparable on EV-based therapeutic strategy for wound healing and regenerative indications, though with regional (Asia) commercial focus versus Phoenestra's global academic/pharma channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/phoenestra

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phoenestra